No Data
No Data
Lifotronic Technology to Build Industrial Base for 1 Billion Yuan; Shares Up 4%
Shenzhen Lifotronic Technology (SHA:688389), through unit Shenzhen Pumen Technology, plans to invest 1 billion yuan to build an in-vitro diagnostic reagent industrial base, according to the company's
Express News | Shenzhen Lifotronic Says It Plans to Invest 1 Bln Yuan in External Diagnostic Reagent Project
Shenzhen Lifotronic Technology Co., Ltd.'s (SHSE:688389) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Shenzhen Lifotronic Technology (SHSE:688389) has had a rough month with its share price down 11%. However, stock prices are usually driven by a company's financial performance over the long term, wh
Shareholders of Shenzhen Lifotronic Technology Co., Ltd. (688389.SH) plan to reduce their shareholding by no more than 2.5% in total.
Pumeng Technology (688389.SH) announced that shareholder Xiamen Hanyu Investment Consulting Partnership Enterprise (Limited Partnership) (referred to as 'Xiamen Hanyu'), Xiamen Qiaochuan Investment Partnership Enterprise (Limited Partnership) (referred to as 'Xiamen Qiaochuan'), Xiamen Purong Investment Partnership Enterprise (Limited Partnership) (referred to as 'Xiamen Purong'), director and deputy general manager Li Dawei and supervisor Yang Jun plan to reduce their shareholding within three months after 15 trading days from the announcement of this plan, and within any consecutive 90 days, reduce no more than 4.2842 million shares in total through centralized bidding, which is no more than 1% of the total share capital of the company.
An Intrinsic Calculation For Shenzhen Lifotronic Technology Co., Ltd. (SHSE:688389) Suggests It's 27% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Shenzhen Lifotronic Technology fair value estimate is CN¥26.77 Shenzhen Lifotronic Technology's CN¥19.48 share price signals that it might be
Shenzhen Lifotronic Technology Co., Ltd.'s (SHSE:688389) Market Cap Increased by CN¥634m, Insiders Receive a 46% Cut
Key Insights Insiders appear to have a vested interest in Shenzhen Lifotronic Technology's growth, as seen by their sizeable ownership 53% of the business is held by the top 6 shareholders 23% of
No Data